Roivant Sciences (FRA:87S) Piotroski F-Score: 0 (As of Jun. 26, 2026)


FRA:87S Roivant Sciences Ltd FRA:87S
55 GF Score
Price €30.01
GF Value €8.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 0 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Roivant Sciences has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Roivant Sciences's Piotroski F-Score or its related term are showing as below:

During the past 6 years, the highest Piotroski F-Score of Roivant Sciences was 5. The lowest was 0. And the median was 3.

Roivant Sciences  (FRA:87S) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Roivant Sciences Piotroski F-Score Related Terms


Roivant Sciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Piotroski F-Score Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial N/A 2.00 5.00 3.00 0.00

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 2.00 2.00 0.00
FRA:87S
55GF Score
Roivant Sciences Ltd FRA:87S
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -193.649 + -96.718 + -227.071 + 262.09 = €-255.35 Mil.
Cash Flow from Operations was -177.2 + -158.186 + -167.797 + -141.703 = €-644.89 Mil.
Revenue was 1.881 + 1.338 + 1.707 + 2.18 = €7.11 Mil.
Gross Profit was 1.748 + 1.244 + 1.109 + 1.903 = €6.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(5029.169 + 4363.266 + 4313.333 + 4462.464 + 4938.014) / 5 = €4621.2492 Mil.
Total Assets at the begining of this year (Mar25) was €5,029.17 Mil.
Long-Term Debt & Capital Lease Obligation was €83.29 Mil.
Total Current Assets was €4,469.79 Mil.
Total Current Liabilities was €243.28 Mil.
Net Income was 88.531 + -207.396 + 161.759 + -190.989 = €-148.10 Mil.

Revenue was 7.423 + 4.032 + 8.612 + 7.002 = €27.07 Mil.
Gross Profit was 7.225 + 3.821 + 8.365 + 6.813 = €26.22 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(6644.683 + 6035.2 + 5591.631 + 5531.689 + 5029.169) / 5 = €5766.4744 Mil.
Total Assets at the begining of last year (Mar24) was €6,644.68 Mil.
Long-Term Debt & Capital Lease Obligation was €83.55 Mil.
Total Current Assets was €4,625.06 Mil.
Total Current Liabilities was €138.21 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Roivant Sciences's current Net Income (TTM) was -255.35. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Roivant Sciences's current Cash Flow from Operations (TTM) was -644.89. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-255.348/5029.169
=-0.0507734

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-148.095/6644.683
=-0.02228774

Roivant Sciences's return on assets of this year was -0.0507734. Roivant Sciences's return on assets of last year was -0.02228774. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Roivant Sciences's current Net Income (TTM) was -255.35. Roivant Sciences's current Cash Flow from Operations (TTM) was -644.89. ==> -644.89 <= -255.35 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=83.292/4621.2492
=0.0180237

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=83.553/5766.4744
=0.01448944

Roivant Sciences's gearing of this year was 0.0180237. Roivant Sciences's gearing of last year was 0.01448944. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=4469.787/243.276
=18.37331673

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=4625.059/138.205
=33.46520748

Roivant Sciences's current ratio of this year was 18.37331673. Roivant Sciences's current ratio of last year was 33.46520748. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Roivant Sciences's number of shares in issue this year was 717.301. Roivant Sciences's number of shares in issue last year was 707.628. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=6.004/7.106
=0.84491979

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=26.224/27.069
=0.96878348

Roivant Sciences's gross margin of this year was 0.84491979. Roivant Sciences's gross margin of last year was 0.96878348. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=7.106/5029.169
=0.00141296

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=27.069/6644.683
=0.00407378

Roivant Sciences's asset turnover of this year was 0.00141296. Roivant Sciences's asset turnover of last year was 0.00407378. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+0+0+0+0
=0

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Roivant Sciences has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

Is Roivant Sciences (FRA:87S) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of €30.01 is trading 250.6% above its estimated GF Value™ of €8.56. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for FRA:87S:

  • Piotroski F-Score: 0
  • GF Value™: €8.56 vs. price of €30.01 (250.6% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the FRA:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for FRA:87S

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.01
Price
€8.56
GF Value